Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2b + ribavirin

Drug Profile

Peginterferon alfa-2b + ribavirin

Alternative Names: Cotronak + peginterferon alfa-2b; PEG interferon-alpha-2b + ribavirin; PEG-Intron + REBETOL; PEG-Rebetron; Pegetron; Pegylated interferon-alpha-2b + ribavirin; Ribavirin + peginterferon alfa-2b; SCH-54031 + SCH-18908

Latest Information Update: 17 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Interferons; Nucleosides
  • Mechanism of Action Enzyme inhibitors; Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 09 Apr 2015 Merck Sharp & Dohme terminates phase III trial in Hepatitis C (in type C compensated liver cirrhosis patients) in Japan (NCT00811967)
  • 17 Jul 2013 The UK's National Institute for Health and Care Excellence issues draft guidance recommending peginterferon alfa-2b in combination with ribavirin for Hepatitis C (in children, in adolescents)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top